NCT05118178 (ANTEC) is a clinical trial of echocardiography, computed tomography in Cardiotoxicity, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology.

Who is sponsoring NCT05118178?

NCT05118178 is sponsored by Maria Sklodowska-Curie National Research Institute of Oncology.

What drugs are being tested in NCT05118178?

Interventions in NCT05118178: echocardiography, computed tomography.

What condition does NCT05118178 study?

NCT05118178 studies Cardiotoxicity, Atherosclerosis.

Is NCT05118178 still recruiting?

NCT05118178 is currently completed. Last updated 25 June 2025.

Last reviewed 2025-06-25 · How we verify

NCT05118178: ANTEC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atherosclerosis in Chemotherapy-related Cardiotoxicity

Completed Last updated 25 June 2025

What this trial tests

trial testing echocardiography, computed tomography in Cardiotoxicity in 80 participants. Completed in 15 March 2025.

Timeline

15 November 2021

Primary endpoint
15 September 2024

15 March 2025

Quick facts

Lead sponsor	Maria Sklodowska-Curie National Research Institute of Oncology
Status	Completed
Study type	OBSERVATIONAL
Enrollment	80
Start date	15 November 2021
Primary completion	15 September 2024
Estimated completion	15 March 2025
Sites	1 location across Poland

Drugs / interventions tested

echocardiography, computed tomography

Conditions studied

Cardiotoxicity — all drugs for Cardiotoxicity →
Atherosclerosis — all drugs for Atherosclerosis →

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology

Who can join

Eligibility, any sex, with Cardiotoxicity or Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiological complications of oncological treatment, including the most serious of them cardiotoxicity and heart failure, constitute a significant and still unsolved clinical problem. A history of hypercholesterolaemia and coronary artery disease in cancer patients, is one of the risk factors for cardiotoxicity. In recent years, a protective effect of statin treatment on the development of heart failure in cancer patients has been observed. ANTEC (Atherosclerosis iN chemoTherapy-rElated Cardiotoxicity) is a prospective observational study aimed at assessing the impact of the advancement of atherosclerotic lesions in the coronary arteries assessed in computed tomography on the development of left ventricular systolic dysfunction in cancer patients at high risk of myocardial damage. A group of 80 patients diagnosed with cancer before starting high-dose anthracycline chemotherapy (doxorubicin ≥ 240 mg / m2 or epirubicin ≥ 600 mg / m2 body weight), without a history of heart failure and coronary artery disease, will be included in the study. The total follow-up of patients was planned for 12 months. The primary endpoint is time to onset of left ventricular systolic dysfunction as assessed by echocardiography. The secondary composite endpoints include all-cause death, cardiovascular death, myocardial infarction, and stroke. Additionally, the assessment will include: the severity of atherosclerotic changes in the coronary arteries and the calcification index in computed tomography, the percentage decrease in left ventricular ejection fraction, GLS (global longitudinal strain) in echocardiography, and changes in the concentration of biomarkers involved in inflammatory and atherosclerotic processes. This is the first study of this type, which we hope will contribute to a better understanding of the pathophysiology of cardiotoxicity development and to changing the standards of management of oncological patients and improving survival in this group of patients.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC study.
Borowiec A, Ozdowska P, Rosinska M, Jagiello-Gruszfeld A, et al · · 2023 · cited 7× · PMID 37590267 · DOI 10.1371/journal.pone.0288146
Coronary artery calcium score and other risk factors in patients at moderate and high risk of cancer therapy-related cardiovascular toxicity.
Borowiec A, Ozdowska P, Rosinska M, Zebrowska AM, et al · · 2024 · cited 3× · PMID 39342402 · DOI 10.1186/s40959-024-00266-6
Coronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study.
Borowiec A, Ozdowska P, Rosinska M, Zebrowska AM, et al · · 2025 · cited 1× · PMID 40872494 · DOI 10.3390/ph18081102
Interleukin-6 in Anthracycline-Related Cardiac Dysfunction: A Comparison with Myeloperoxidase and TNF-Alpha.
Borowiec A, Ozdowska P, Rosinska M, Zebrowska AM, et al · · 2025 · cited 1× · PMID 40362309 · DOI 10.3390/ijms26094071
Predictive Value of Baseline Left Ventricular Global Longitudinal Strain for Cardiac Dysfunction in Patients with Moderate to High Risk of Cancer Therapy-Related Cardiovascular Toxicity.
Borowiec A, Ozdowska P, Rosinska M, Zebrowska AM, et al · · 2025 · PMID 41155645 · DOI 10.3390/ph18101530

Verify or expand the search:

Other recruiting trials for Cardiotoxicity

Currently open trials in the same condition.

NCT07442578 — Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial · NA · active not recruiting
NCT06778122 — In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors · NA · recruiting
NCT07382141 — Early Identification of Cardivascular Damage Induced by Chemotherapy and Antineoplastic Treatments in Pediatric Age · NA · recruiting
NCT06595147 — Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study · NA · recruiting
NCT06270667 — Effects of Exercise Training in Survivors of Lymphoma · NA · recruiting

Other Maria Sklodowska-Curie National Research Institute of Oncology trials

Trials by the same sponsor.

NCT07216157 — NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery · NA · recruiting
NCT06472583 — Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast C · Phase 2 · recruiting
NCT05271162 — Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines · Phase 3 · recruiting
NCT06201078 — Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy · Phase 2 · recruiting
NCT06128863 — Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tiss · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05118178 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maria Sklodowska-Curie National Research Institute of Oncology
Last refreshed: 25 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05118178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing